Adicet Bio, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Chen Schor
- Full Time Employees
- 102
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 131 Dartmouth Street Boston MA United States 02116
- IPO Date
- Jan 26, 2018
- CIK
- 0001720580
- Website
- adicetbio.com
- Similar Companies
- Business
- Adicet Bio, Inc. is a clinical-stage biotechnology company that develops allogeneic gamma delta T cell therapies designed to treat autoimmune diseases and various cancers. Its primary products include engineered gamma delta T cells with chimeric antigen receptors (CARs) that enhance immune targeting and durable activity. The company’s lead product candidate, ADI-001, is an allogeneic gamma delta CAR T cell therapy targeting CD20, currently in Phase 1 clinical trials for autoimmune diseases such as lupus nephritis and relapsed/refractory B-cell non-Hodgkin’s lymphoma. Adicet also develops ADI-270, an armored gamma delta CAR T cell product candidate targeting CD70 for multiple solid tumors and hematological malignancies, including renal cell carcinoma. The company operates primarily in the United States and focuses on oncology and immunology sectors by harnessing gamma delta T cells' innate tumor-targeting capabilities. Founded in 2014 and headquartered in Boston, Massachusetts, Adicet Bio’s business model centers on off-the-shelf allogeneic cell therapies, aiming to provide accessible and effective treatments. The company has established strategic partnerships, including one with MaxCyte, which enhances its manufacturing capabilities through proprietary non-viral gene editing technologies. Recently, it completed a $74.8 million net financing extending its cash runway into the second half of 2027, supporting ongoing clinical development and manufacturing scale-up. In 2025, Adicet reported positive preliminary Phase 1 data for ADI-001 in autoimmune diseases, demonstrating rapid reductions in disease activity and improved renal function with favorable safety profiles. It initiated a Phase 1 trial for rheumatoid arthritis and plans to start a pivotal ADI-001 study in 2026 following an FDA meeting. These recent developments underscore Adicet’s expanded pipeline and strategic focus on autoimmune disorders and oncology. Adicet Bio’s innovative platform leverages the unique biological properties of gamma delta T cells to target solid tumors and hematologic cancers with novel specificity and improved safety margins compared to traditional alpha beta T cell therapies. Its therapies are engineered for availability on demand and best-in-class drug exposure, addressing unmet medical needs globally. The company maintains ongoing clinical and preclinical programs to expand its pipeline and advance the cell therapy field, highlighting its commitment to transforming treatment landscapes in oncology and autoimmune diseases through scientific and manufacturing excellence.
Company News
Adicet Bio's Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis Transcript
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio Announces FDA Clearance of IND Application for ADI-212
Here's Why You Should Add ACET Stock to Your Portfolio Now
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Adicet Bio: A Cheap Gamma Delta T-Cell Play
Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet
Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy
All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy
Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
Lipocine Appoints Michael J. Grissinger to Board of Directors